Biohaven Pharmaceutical Holding (BHVN) PT Raised to $165 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- US stock futures gain ahead of July inflation data
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $160 at H.C. Wainwright
October 6, 2021 6:39 AM EDTH.C. Wainwright analyst Douglas Tsao raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $160.00 (from $135.00) while maintaining a Buy rating.
The analyst commented, "Nurtec once again exceeded expectations, demonstrating the strong commercial execution as well as the drugs unique profile both treating and preventing migraines. Preliminary sales clocked in at $136M, up 46% Q/Q; about 33% above our estimates at $102M and roughly 20% above consensus at... More
